Information you can trust.

MEN1 syndrome (Multiple Endocrine Neoplasia type 1)

MEN1 is a rare inherited condition that causes tumours in the endocrine glands – the parathyroids, pituitary and pancreas. What it is, what causes it, and how it is diagnosed.

Types of scans for NET Cancers

There are various types of scans that may or may not be suitable for your type of NETs. Here is a summary of some scans you might encounter.

Grades of Neuroendocrine (NET) Cancers

What G1, G2 and G3 mean for a neuroendocrine cancer diagnosis – plain-language explanation of grade, Ki-67, and how they shape treatment options.

Types of Neuroendocrine Tumours

Neuroendocrine Tumours (NETs) is an umbrella name for a number of different types of tumours, which can arise in different areas of the body. It can be…

PRRT patient guide

Patient guide to peptide receptor radionuclide therapy (PRRT) for NETs.

Treatments for NETs

Treatments for neuroendocrine cancers vary from person to person and may be one or more of the options listed below.

Glossary

Plain-language definitions of common neuroendocrine tumour (NET) terms – for patients, whānau, and care partners. Updated as new treatments and tests come into NZ practice.

A second PRRT in the FDA pipeline: 177Lu-edotreotide decision due August 2026

The FDA is expected to decide on ITM-11 (177Lu-edotreotide) for GEP-NETs by 28 August 2026, based on the Phase 3 COMPETE trial results.

Early signals from alpha-emitter PRRT in SSTR2-positive NETs

A first-in-human trial of [212Pb]VMT-α-NET, a targeted alpha-particle therapy for SSTR2-positive NETs, has reported early activity at ASCO GI 2026.

Understanding Neuroendocrine

Neuroendocrine tumours (NETs) is the umbrella term for a group of unusual, often slow-growing cancers.

Cabozantinib approved by the FDA for previously treated advanced NETs

The CABINET trial led the FDA to approve cabozantinib in March 2025 for adults and adolescents with previously treated advanced pancreatic and extra-pancreatic NETs.

NETTER-2 supports PRRT as a first-line option in advanced GEP-NETs

The Phase 3 NETTER-2 trial showed Lutathera plus octreotide nearly tripled progression-free survival when used as first-line therapy in grade 2/3 GEP-NETs.

Paragangliomas and Pheochromocytomas - July 2024

When NET cancers run in families: inherited syndromes

Most neuroendocrine cancers aren't inherited, but a small number are linked to hereditary syndromes like MEN1, MEN2 and VHL. Here's what to know.

Understanding Neuroendocrine (NET) Cancers

Neuroendocrince Cancer NZ is an organisation dedicated to revolutionising the way that neuroendocrine tumours are diagnosed and managed in New Zealand.

NET Resources

Revisit past presentations from NET Cancer specialists at Unicorn Foundation NZ's NET Cancer Education Days.

About PRRT - Dr Rachelle Steyn

Carcinoid Heart Disease & Surgery - Dr Boris Lowe July 2022

Genetics and NETS - Dr Veronica Boyle

Radiology in Neuroendocrine Tumours

Can we improve monitoring of people with NETs?

Dietary Management of Diarrhoea in NETs - Olivia Cochrane